Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Ahmed S. Kenawy"'
Autor:
Mohammed K. Afifi, Ahmed S. Kenawy, Heba H. El Demellawy, Amany A. Azouz, Torki Al-Otaibi, Osama Gheith, Mohamed Abd ElMonem, Mohamed S. AbdElhalim, Raghda R. S. Hussein
Publikováno v:
Future Journal of Pharmaceutical Sciences, Vol 7, Iss 1, Pp 1-7 (2021)
Abstract Background Osteoporosis and osteopenia occur frequently in renal transplant recipients due to long-term use of immune-suppressants including corticosteroids. Previous treatment options like bisphosphonates had acceptable but rather unsatisfa
Externí odkaz:
https://doaj.org/article/43a3a8f01b2a442087716d99e6b0b46f
Autor:
Mohamed S. AbdElhalim, Ahmed S. Kenawy, Heba H. El Demellawy, Amany A. Azouz, Sarah S. Alghanem, Torki Al-Otaibi, Osama Gheith, Mohamed Abd ElMonem, Mohammed K. Afifi, Raghda R. S. Hussein
Publikováno v:
Kidney Research and Clinical Practice, Vol 39, Iss 4, Pp 479-486 (2020)
Background : The absorption rates of mycophenolate mofetil (MMF) and enteric-coated mycophenolate sodium (EC-MPS) may be influenced by the concomitant use of omeprazole. Methods : One hundred kidney transplant patients were recruited during their out
Externí odkaz:
https://doaj.org/article/7e2899e0b9724c9b94979efb5372259f
Autor:
Sarah S. Alghanem, Moetaza M. Soliman, Ali A. Alibrahim, Osama Gheith, Ahmed S. Kenawy, Abdelmoneim Awad
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2020)
Background: There is a lack of data in the literature on the evaluation of tacrolimus (TAC) dosage regimen and monitoring after kidney transplantation (KT) in Kuwait. The aim of the present study was to evaluate TAC dosing in relation to the hospital
Externí odkaz:
https://doaj.org/article/6bf8dc419d1041999a5a328f54fbee78
Publikováno v:
Egyptian Journal of Chest Disease and Tuberculosis, Vol 69, Iss 3, Pp 549-559 (2020)
Background Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and fatal disease, with a median survival of ∼2–5 years. The main target of treatment was to stabilize or reduce the rate of disease progression. Nintedanib and pirfenidone
Externí odkaz:
https://doaj.org/article/66e59a109cd84a32aff1e988f0c227cb
Autor:
Mohamed Abd ElMonem, Mohamed S. AbdElhalim, Ahmed S. Kenawy, Mohammed K. Afifi, Raghda R S Hussein, Heba H. El Demellawy, Osama Gheith, Torki Al-Otaibi, Amany A. Azouz
Publikováno v:
Future Journal of Pharmaceutical Sciences, Vol 7, Iss 1, Pp 1-7 (2021)
Background Osteoporosis and osteopenia occur frequently in renal transplant recipients due to long-term use of immune-suppressants including corticosteroids. Previous treatment options like bisphosphonates had acceptable but rather unsatisfactory res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21900cdd4a3c135ef5c720e54efc2447
https://doi.org/10.1186/s43094-021-00378-1
https://doi.org/10.1186/s43094-021-00378-1
Autor:
Nashwa Othman, Ahmed S. Kenawy, Mohamed Sobhy Nagy, Osama Gheith, Mohamed Al-Otaibi, Hasaneen Abo Atya, Torky Al-Otaibi
Publikováno v:
Patient Preference and Adherence. 13:1477-1486
Introduction and aim Kidney transplantation is the optimal treatment choice for end stage renal disease; this option needs a major change in the recipients' lifestyle and requires strict adherence to medications. The study aim was to assess the compl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a9af5ec6ae34fafdda09a5df6e162088
https://doi.org/10.2147/ppa.s209212
https://doi.org/10.2147/ppa.s209212
Publikováno v:
Egyptian Journal of Chest Disease and Tuberculosis, Vol 69, Iss 3, Pp 549-559 (2020)
Background Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and fatal disease, with a median survival of ∼2–5 years. The main target of treatment was to stabilize or reduce the rate of disease progression. Nintedanib and pirfenidone
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf3efd68702099d8e5a0f4c3b66dafc2
https://doi.org/10.4103/ejcdt.ejcdt_140_19
https://doi.org/10.4103/ejcdt.ejcdt_140_19